After a federal Risperdal lawsuit settlement in November 2013, patients are coming forward with personal injury lawsuits against Johnson & Johnson and its subsidiary Janssen Pharmaceuticals. The company paid more than $2.2 billion to settle criminal and civil claims that it promoted its antipsychotic drug Risperdal for off-label uses.
The U.S. Department of Justice alleged that Janssen promoted Risperdal for behavioral disturbances in children, though it has not been approved for such uses. Risperdal use in children and adolescents has been linked to gynecomastia, the development of breast tissue in males.
Hundreds of patients have brought Risperdal complaints forward after the federal settlement, claiming that Risperdal has led to unwanted breast growth. As much as 25% of cases of gynecomastia breast growth in males has been attributed to drug use, including Risperdal.